000			02280 a2200661 4500
005			20250516141510.0
264		0	_c20140213
008			201402s 0 0 eng d
022			_a1527-3350
024	7		_a10.1002/hep.26388 _2doi
040			_aNLM _beng _cNLM
100	1		_aMcPhee, Fiona
245	0	0	_aResistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. _h[electronic resource]
260			_bHepatology (Baltimore, Md.) _cSep 2013
300			_a902-11 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aCarbamates
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Resistance, Viral _xgenetics
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aHepacivirus _xgenetics
650	0	4	_aHepatitis C, Chronic _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aInterferons
650	0	4	_aInterleukins _xgenetics
650	0	4	_aIsoquinolines _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolyethylene Glycols _xtherapeutic use
650	0	4	_aPyrrolidines
650	0	4	_aRNA, Viral _xgenetics
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aTreatment Failure
650	0	4	_aTreatment Outcome
650	0	4	_aValine _xanalogs & derivatives
650	0	4	_aViral Nonstructural Proteins _xgenetics
700	1		_aHernandez, Dennis
700	1		_aYu, Fei
700	1		_aUeland, Joseph
700	1		_aMonikowski, Aaron
700	1		_aCarifa, Arlene
700	1		_aFalk, Paul
700	1		_aWang, Chunfu
700	1		_aFridell, Robert
700	1		_aEley, Timothy
700	1		_aZhou, Nannan
700	1		_aGardiner, David
773	0		_tHepatology (Baltimore, Md.) _gvol. 58 _gno. 3 _gp. 902-11
856	4	0	_uhttps://doi.org/10.1002/hep.26388 _zAvailable from publisher's website
999			_c22591621 _d22591621